VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...
Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...
The American Journal of Managed Care® is the leading peer-reviewed journal dedicated to issues in managed care. Founded in 1995, it is an independent, peer-reviewed, monthly publication dedicated to ...
IDOV-Safe leverages an unusually high extracellular enveloped virion proportion (~60%) to support true intravenous oncolytic virus delivery despite circulating neutralizing proteins. The phase 1 ...
Reimbursement uncertainty and absent permanent billing codes remain dominant CGT access barriers, exposing limitations of “buy-and-bill” models and necessitating dedicated staffing and early ...
Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...
From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...
As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...
Development is moving to phase 2 LEGION-100-2a (NCT06533644) across global sites, with planned neoadjuvant prostate studies and expansion concepts in multiple solid tumors. Metastatic ...
This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic ...
The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...
Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results